Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial

In this RCT, addition of voclosporin, a novel calcineurin inhibitor, to mycophenolate mofetil (MMF) and low-dose steroids led to superior complete renal response rate at week 52 vs MMF and low dose steroids (n=179; 41% vs 23%; OR 2.65; 95% CI 1.64–4.27; p<0.0001).

Source:

The Lancet